Tapewire

Nasdaq · USD

ELVN

Enliven Therapeutics, Inc.

Export transactions ↓
Tapewire entity
4024
SEC CIK
0001672619
Parsed reports
377

Last 12 months

Inside the activity.

0 purchase rows · 74 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202505
Dec 202503
Jan 2026013
Feb 202603
Mar 202605
Apr 202603
May 202603
Jun 2026015
Jul 2026012
Aug 202605
Sep 202606
Oct 202601

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
February 12, 2026 Filed Feb 18, 2026 00:53 UTC
Patel AnishCHIEF OPERATING OFFICER
GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0001967163-26-000002 · form4-02182026_120233.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F1 · balance_after: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
February 12, 2026 Filed Feb 18, 2026 00:56 UTC
Bauer JakeDirector
GrantStock Option (right to buy) · Derivative 17,126 $0.00 Strike: $27.16 $0.00
Disclosure

SEC source: 0001654909-26-000001 · form4-02182026_120203.xml · derivative · entry 1

Bauer Jake · CIK 0001654909 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,126

Underlying: Common Stock · 17,126 shares

Expires 2036-02-12

F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.

Read SEC document
February 12, 2026 Filed Feb 18, 2026 00:49 UTC
Hohl BenjaminCHIEF FINANCIAL OFFICER
GrantStock Option (right to buy) · Derivative 150,000 $0.00 Strike: $27.16 $0.00
Disclosure

SEC source: 0001882764-26-000001 · form4-02182026_120228.xml · derivative · entry 2

Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2036-02-12

F3 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
February 12, 2026 Filed Feb 18, 2026 00:49 UTC
Hohl BenjaminCHIEF FINANCIAL OFFICER
GrantCommon Stock 25,000 $0.00 $0.00
Disclosure

SEC source: 0001882764-26-000001 · form4-02182026_120228.xml · nonDerivative · entry 1

Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,000

F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F2 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Read SEC document
February 12, 2026 Filed Feb 18, 2026 00:47 UTC
Collins Helen LouiseCHIEF MEDICAL OFFICER
GrantStock Option (right to buy) · Derivative 150,000 $0.00 Strike: $27.16 $0.00
Disclosure

SEC source: 0001701247-26-000001 · form4-02182026_120250.xml · derivative · entry 2

Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2036-02-12

F2 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
February 12, 2026 Filed Feb 18, 2026 00:47 UTC
Collins Helen LouiseCHIEF MEDICAL OFFICER
GrantCommon Stock 25,000 $0.00 $0.00
Disclosure

SEC source: 0001701247-26-000001 · form4-02182026_120250.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F1 · balance_after: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
February 06, 2026 Filed Feb 10, 2026 18:12 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 5,000 $29.04 $145,219.00
Disclosure

SEC source: 0001967150-26-000003 · form4-02102026_110257.xml · nonDerivative · entry 1

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 740,188

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $28.925 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 17:34 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 14,509 $26.90 $390,284.85
Disclosure

SEC source: 0001967150-26-000002 · form4-01222026_100144.xml · nonDerivative · entry 2

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 745,188

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $26.6137 to $27.344. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 17:34 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 5,491 $26.37 $144,814.14
Disclosure

SEC source: 0001967150-26-000002 · form4-01222026_100144.xml · nonDerivative · entry 1

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 759,697

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $25.605 to $26.5928. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 22:33 UTC SaleCommon Stock 718 $26.96 $19,354.41
Disclosure

SEC source: 0001584759-26-000007 · form4-01222026_100111.xml · nonDerivative · entry 2

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 23,877

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust").

F4 · price: This transaction was executed in multiple trades at prices ranging from $26.725 to $27.3454. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held of record by the Heyman Daigle Trust.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 22:33 UTC SaleCommon Stock 512 $26.46 $13,547.11
Disclosure

SEC source: 0001584759-26-000007 · form4-01222026_100111.xml · nonDerivative · entry 1

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 24,595

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust").

F2 · price: This transaction was executed in multiple trades at prices ranging from $25.7133 to $26.7111. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held of record by the Heyman Daigle Trust.

Read SEC document
January 09, 2026 Filed Jan 12, 2026 17:12 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 50,000 $29.13 $1,456,715.00
Disclosure

SEC source: 0001967150-26-000001 · form4-01122026_100153.xml · nonDerivative · entry 4

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 765,188

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F6 · price: This transaction was executed in multiple trades at prices ranging from $28.90 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
January 09, 2026 Filed Jan 12, 2026 17:12 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 41,198 $24.90 $1,025,863.16
Disclosure

SEC source: 0001967150-26-000001 · form4-01122026_100153.xml · nonDerivative · entry 3

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 815,188

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F5 · price: This transaction was executed in multiple trades at prices ranging from $24.90 to $24.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
January 09, 2026 Filed Jan 12, 2026 22:11 UTC SaleCommon Stock 4,285 $25.00 $107,125.43
Disclosure

SEC source: 0001584759-26-000004 · form4-01122026_100112.xml · nonDerivative · entry 3

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 25,107

F3 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust").

F6 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5 · ownership.nature: The shares are held of record by the Heyman Daigle Trust.

Read SEC document
January 09, 2026 Filed Jan 13, 2026 22:54 UTC
Patel AnishCHIEF OPERATING OFFICER
SaleCommon Stock 243 $28.50 $6,925.50
Disclosure

SEC source: 0001967163-26-000001 · form4-01132026_100110.xml · nonDerivative · entry 2

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 215,011

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").

F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust.

Read SEC document
January 09, 2026 Filed Jan 13, 2026 22:54 UTC
Patel AnishCHIEF OPERATING OFFICER
SaleCommon Stock 48,057 $27.98 $1,344,836.70
Disclosure

SEC source: 0001967163-26-000001 · form4-01132026_100110.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 215,254

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").

F2 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $28.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust.

Read SEC document
January 08, 2026 Filed Jan 12, 2026 17:12 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 33,802 $24.92 $842,474.29
Disclosure

SEC source: 0001967150-26-000001 · form4-01122026_100153.xml · nonDerivative · entry 2

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 856,386

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $24.90 to $25.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
January 08, 2026 Filed Jan 12, 2026 17:12 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 7,500 $20.13 $150,961.50
Disclosure

SEC source: 0001967150-26-000001 · form4-01122026_100153.xml · nonDerivative · entry 1

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 890,188

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.025 to $20.205. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
January 08, 2026 Filed Jan 12, 2026 22:11 UTC SaleCommon Stock 8,015 $25.04 $200,655.53
Disclosure

SEC source: 0001584759-26-000004 · form4-01122026_100112.xml · nonDerivative · entry 2

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 29,392

F3 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust").

F4 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5 · ownership.nature: The shares are held of record by the Heyman Daigle Trust.

Read SEC document
January 08, 2026 Filed Jan 12, 2026 22:11 UTC SaleCommon Stock 1,620 $25.00 $40,500.00
Disclosure

SEC source: 0001584759-26-000004 · form4-01122026_100112.xml · nonDerivative · entry 1

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 25,545

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by RAHD Capital LLC, for which the Reporting Person serves as a managing member.

F2 · ownership.nature: The shares are held of record by RAHD Capital LLC.

Read SEC document
January 07, 2026 Filed Jan 9, 2026 23:10 UTC GrantStock Option (right to buy) · Derivative 59,372 $0.00 Strike: $15.47 $0.00
Disclosure

SEC source: 0001533228-26-000002 · form4-01092026_110126.xml · derivative · entry 1

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,372

Underlying: Common Stock · 59,372 shares

Expires 2036-01-07

F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on February 7, 2026 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.

Read SEC document
December 22, 2025 Filed Dec 23, 2025 23:47 UTC
Hohl BenjaminCHIEF FINANCIAL OFFICER
Exercise / conversionStock Option (right to buy) · Derivative 13,000 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001882764-25-000005 · form4-12232025_111212.xml · derivative · entry 2

Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,056

Underlying: Common Stock · 13,000 shares

Expires 2031-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Read SEC document
December 22, 2025 Filed Dec 23, 2025 23:47 UTC
Hohl BenjaminCHIEF FINANCIAL OFFICER
Exercise / conversionCommon Stock 13,000 $2.48 $32,240.00
Disclosure

SEC source: 0001882764-25-000005 · form4-12232025_111212.xml · nonDerivative · entry 1

Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 19, 2025 Filed Dec 23, 2025 18:45 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 5,000 $16.84 $84,206.00
Disclosure

SEC source: 0001967150-25-000008 · form4-12232025_111217.xml · nonDerivative · entry 1

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 897,688

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $16.605 to $17.115. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 22:58 UTC Exercise / conversionStock Option (right to buy) · Derivative 15,958 $0.00 Strike: $1.12 $0.00
Disclosure

SEC source: 0001536368-25-000007 · form4-12192025_101209.xml · derivative · entry 3

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,741

Underlying: Common Stock · 15,958 shares

Expires 2030-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 22:58 UTC Exercise / conversionCommon Stock 15,958 $1.12 $17,872.96
Disclosure

SEC source: 0001536368-25-000007 · form4-12192025_101209.xml · nonDerivative · entry 1

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,712

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 11, 2025 Filed Dec 12, 2025 23:31 UTC
Fair Richard A.Director · PRESIDENT AND CEO
GrantStock Option (right to buy) · Derivative 875,000 $0.00 Strike: $18.77 $0.00
Disclosure

SEC source: 0001695851-25-000004 · form4-12122025_111226.xml · derivative · entry 1

Fair Richard A. · CIK 0001695851 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 875,000

Underlying: Common Stock · 875,000 shares

Expires 2035-12-11

F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on December 11, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
December 08, 2025 Filed Dec 10, 2025 22:13 UTC
Patel AnishCHIEF OPERATING OFFICER
SaleCommon Stock 1,705 $21.78 $37,133.88
Disclosure

SEC source: 0001967163-25-000005 · form4-12102025_101217.xml · nonDerivative · entry 2

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 263,311

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").

F4 · price: This transaction was executed in multiple trades at prices ranging from $21.51 to $22.055. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust.

Read SEC document
December 08, 2025 Filed Dec 10, 2025 22:13 UTC
Patel AnishCHIEF OPERATING OFFICER
SaleCommon Stock 4,958 $20.76 $102,938.99
Disclosure

SEC source: 0001967163-25-000005 · form4-12102025_101217.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 265,016

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.51 to $21.495. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust.

Read SEC document
November 19, 2025 Filed Nov 21, 2025 17:28 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 492 $23.09 $11,360.77
Disclosure

SEC source: 0001967150-25-000007 · form4-11212025_101158.xml · nonDerivative · entry 2

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 902,688

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $23.045 to $23.165. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
November 19, 2025 Filed Nov 21, 2025 17:28 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 12,008 $22.30 $267,794.01
Disclosure

SEC source: 0001967150-25-000007 · form4-11212025_101158.xml · nonDerivative · entry 1

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 903,180

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $22.035 to $23.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 18:45 UTC
Kintz SamuelDirector · PRESIDENT AND CEO
SaleCommon Stock 12,500 $21.82 $272,738.75
Disclosure

SEC source: 0001967168-25-000008 · form4-11192025_111110.xml · nonDerivative · entry 1

Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 890,392

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $21.37 to $22.3537. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 22:34 UTC
Patel AnishCHIEF OPERATING OFFICER
SaleCommon Stock 613 $17.94 $10,995.44
Disclosure

SEC source: 0001967163-25-000004 · form4-11122025_101156.xml · nonDerivative · entry 2

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 269,974

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").

F4 · price: This transaction was executed in multiple trades at prices ranging from $17.835 to $18.265. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 22:34 UTC
Patel AnishCHIEF OPERATING OFFICER
SaleCommon Stock 6,054 $17.35 $105,038.72
Disclosure

SEC source: 0001967163-25-000004 · form4-11122025_101156.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 270,587

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").

F2 · price: This transaction was executed in multiple trades at prices ranging from $16.825 to $17.8248. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust.

Read SEC document
October 20, 2025 Filed Oct 22, 2025 19:20 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 12,500 $22.08 $276,025.00
Disclosure

SEC source: 0001967150-25-000006 · form4-10222025_111054.xml · nonDerivative · entry 1

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 915,188

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $21.285 to $22.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
October 17, 2025 Filed Oct 21, 2025 18:13 UTC
Kintz SamuelDirector · PRESIDENT AND CEO
SaleCommon Stock 12,500 $21.33 $266,653.75
Disclosure

SEC source: 0001967168-25-000007 · form4-10212025_101038.xml · nonDerivative · entry 1

Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 902,892

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $21.1303 to $21.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

Read SEC document
October 07, 2025 Filed Oct 9, 2025 21:21 UTC
Patel AnishCHIEF OPERATING OFFICER
SaleCommon Stock 6,667 $20.10 $133,992.70
Disclosure

SEC source: 0001967163-25-000003 · form4-10092025_091058.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 276,641

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.0001 to $20.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust.

Read SEC document
September 29, 2025 Filed Oct 1, 2025 20:46 UTC
Hohl BenjaminCHIEF FINANCIAL OFFICER
Exercise / conversionStock Option (right to buy) · Derivative 3,250 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001882764-25-000004 · form4-10012025_081027.xml · derivative · entry 3

Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,056

Underlying: Common Stock · 3,250 shares

Expires 2031-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.

F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Read SEC document
September 29, 2025 Filed Oct 1, 2025 20:46 UTC
Hohl BenjaminCHIEF FINANCIAL OFFICER
SaleCommon Stock 3,250 $20.40 $66,291.23
Disclosure

SEC source: 0001882764-25-000004 · form4-10012025_081027.xml · nonDerivative · entry 2

Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,000

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.025 to $20.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 29, 2025 Filed Oct 1, 2025 20:46 UTC
Hohl BenjaminCHIEF FINANCIAL OFFICER
Exercise / conversionCommon Stock 3,250 $2.48 $8,060.00
Disclosure

SEC source: 0001882764-25-000004 · form4-10012025_081027.xml · nonDerivative · entry 1

Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.

Read SEC document
September 26, 2025 Filed Sep 30, 2025 17:53 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 4,000 $20.25 $81,005.20
Disclosure

SEC source: 0001967150-25-000005 · form4-09302025_090907.xml · nonDerivative · entry 1

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 927,688

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.015 to $20.285. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
September 26, 2025 Filed Sep 30, 2025 17:51 UTC
Kintz SamuelDirector · PRESIDENT AND CEO
SaleCommon Stock 3,700 $20.06 $74,227.55
Disclosure

SEC source: 0001967168-25-000006 · form4-09302025_090944.xml · nonDerivative · entry 1

Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 915,392

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

Read SEC document
September 23, 2025 Filed Sep 25, 2025 19:44 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 1,500 $20.03 $30,045.00
Disclosure

SEC source: 0001967150-25-000004 · form4-09252025_110942.xml · nonDerivative · entry 1

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 931,688

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
September 23, 2025 Filed Sep 25, 2025 19:42 UTC
Kintz SamuelDirector · PRESIDENT AND CEO
SaleCommon Stock 2,800 $20.03 $56,084.00
Disclosure

SEC source: 0001967168-25-000005 · form4-09252025_110953.xml · nonDerivative · entry 1

Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 919,092

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

Read SEC document
September 19, 2025 Filed Sep 19, 2025 19:12 UTC
Kintz SamuelDirector · PRESIDENT AND CEO
SaleCommon Stock 1,000 $20.25 $20,250.00
Disclosure

SEC source: 0001967168-25-000004 · form4-09192025_110913.xml · nonDerivative · entry 2

Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 921,892

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $20.015 to $20.035. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

Read SEC document
September 19, 2025 Filed Sep 23, 2025 17:14 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 2,130 $20.02 $42,634.08
Disclosure

SEC source: 0001967150-25-000003 · form4-09232025_090918.xml · nonDerivative · entry 2

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 933,188

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $19.95 to $20.0469. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
September 19, 2025 Filed Sep 23, 2025 17:14 UTC
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 4,870 $19.11 $93,063.27
Disclosure

SEC source: 0001967150-25-000003 · form4-09232025_090918.xml · nonDerivative · entry 1

Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 935,318

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $18.94 to $19.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Read SEC document
September 17, 2025 Filed Sep 19, 2025 19:12 UTC
Kintz SamuelDirector · PRESIDENT AND CEO
SaleCommon Stock 5,000 $19.09 $95,473.00
Disclosure

SEC source: 0001967168-25-000004 · form4-09192025_110913.xml · nonDerivative · entry 1

Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 922,892

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $18.56 to $19.51. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

Read SEC document
September 08, 2025 Filed Sep 11, 2025 00:12 UTC
Patel AnishCHIEF OPERATING OFFICER
SaleCommon Stock 6,667 $20.24 $134,957.41
Disclosure

SEC source: 0001415889-25-024196 · form4-09112025_120931.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 283,308

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").

F2 · price: This transaction was executed in multiple trades at prices ranging from $19.915 to $20.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust.

Read SEC document
August 27, 2025 Filed Aug 29, 2025 21:03 UTC
Hohl BenjaminCHIEF FINANCIAL OFFICER
Exercise / conversionStock Option (right to buy) · Derivative 3,250 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001415889-25-023310 · form4-08292025_090813.xml · derivative · entry 3

Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,306

Underlying: Common Stock · 3,250 shares

Expires 2031-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.

F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.